Publicacións (49) Publicacións de Silvia Antolín Novoa

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

2023

  1. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  2. Locoregional relapse after sparing mastectomies and immediate reconstruction in women with breast cancer

    Cirugia Espanola, Vol. 101, Núm. 2, pp. 97-106

  3. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

  4. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

  5. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10371, pp. 105-117

2022

  1. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

  2. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study

    Annals of Surgical Oncology, Vol. 28, Núm. 2, pp. 958-967

  2. Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer? (Virchows Archiv, (2021), 479, 4, (853-857), 10.1007/s00428-021-03104-7)

    Virchows Archiv

  3. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

    Virchows Archiv, Vol. 479, Núm. 4, pp. 853-857

  4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  5. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches

    Farmacia Hospitalaria, Vol. 45, pp. 11-37

  6. Trajectories of alcohol consumption during life and the risk of developing breast cancer

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176

2020

  1. Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y)

    Breast Cancer Research

  2. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

    Scientific Reports, Vol. 10, Núm. 1

  3. Serum phospholipids fatty acids and breast cancer risk by pathological subtype

    Nutrients, Vol. 12, Núm. 10, pp. 1-18

2019

  1. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108

  2. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  3. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64